AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition read more…
Read More
0
